Hello XXX, I stated in my last Chairman's Blog post that we were moving forward with IND-enabling and human clinical studies , and that further testing would be done in academia to determine optimal rodent model dosing regimens, which have nothing to do with human dosing regimens.
Why would the Company need to do a retest, and where did this notion come from? It certainly did not come from me. The results are the results. We believe them as they are and there is clear efficacy.
the data did not reach statistical significance. Gerald cannot change that. BTW, if the data was positive the stock would have gone to a dollar or more. As it is the pps is now LESS than it was on Jan 8th.
News 
Market Data 
Discover 
AI
